Asia
Strategic investment in the US-based company complements Advanced MedTech’s non-invasive product portfolio and strengthens its leadership in urology and stone management
Administered once-daily, SOLIQUA® allows patients with uncontrolled type 2 diabetes take charge of their long-term health
The expanded product range offers tailor-made solutions for customers with specific bioprocessing requirements
Companies from across the globe provide updates on their business and pipelines.
Biocon Ltd announced that it has been recognised as the ASIA IP ELITE for the fourth year in a row and its wholly-owned subsidiary Biocon Biologics makes its debut on this prestigious list in 2019 by the IP Business Congress Asia for robust Intellectual Property management and consistent IP value creation.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
Novartis said the acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.
Bio-Thera Solutions, Ltd. announced that the China National Medical Products Administration has approved QLETLI® for all eligible indications of the reference product, Humira®, in China.
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
The trial demonstrated that patients receiving esaxerenone has a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) of 22.1% compared to 4.0% on placebo.
PRESS RELEASES